Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.
Inclusion Criteria:
Exclusion Criteria:
Green Velley, Arizona 85614, United States
Hilleroed, 3400, Denmark
Koebenhavn OE, 2100, Denmark
Fermo FM, 63023, Italy
Trescore Balneario BG, 24069, Italy
Podybus 90153, 5200 ME Den Bosch, Netherlands
Somerset, BA21 4AT, United Kingdom
Wythenshawe, Manchester, M23 9LT, United Kingdom